Palisade Bio (PALI) Other Gross PP&E Adjustments (2011 - 2025)
Palisade Bio (PALI) reported Other Gross PP&E Adjustments of -$1.8 million for Q4 2025, down 40.15% year-over-year from -$3.0 million in Q4 2024, and down 8181.82% on a QoQ basis from -$22000.0 in Q2 2025.
Palisade Bio (PALI) has 15 years of Other Gross PP&E Adjustments data on file, last reported at -$1.8 million in Q4 2025.
- Quarterly Other Gross PP&E Adjustments fell 40.15% year-over-year to -$1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$1.8 million (down 40.15% YoY) and the FY2025 annual result came in at -$1.8 million, down 40.15% from the prior year.
- Other Gross PP&E Adjustments declined to -$1.8 million in Q4 2025 per PALI's latest filing, from -$22000.0 in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$22000.0 in Q2 2025 and bottomed at -$2.3 million in Q4 2022.
- The 5-year median for Other Gross PP&E Adjustments is -$237000.0 (2023), against an average of -$624388.9.
- The widest annual swing landed in 2023, when Other Gross PP&E Adjustments tumbled 329.69%; it then surged 84.51% in 2025.
- Tracing PALI's Other Gross PP&E Adjustments over 5 years: stood at -$1.8 million in 2021, then declined by 22.16% to -$2.3 million in 2022, then rose by 26.03% to -$1.7 million in 2023, then advanced by 22.06% to -$1.3 million in 2024, then tumbled by 40.15% to -$1.8 million in 2025.
- Per Business Quant, the three latest PALI Other Gross PP&E Adjustments figures stand at -$1.8 million (Q4 2025), -$22000.0 (Q2 2025), and -$53000.0 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.82 Mn |
| Dec 31, 2025 | -1.82 Mn |
| Jun 30, 2025 | -22,000.00 |
| Jun 30, 2025 | -22,000.00 |
| Mar 31, 2025 | -53,000.00 |
| Mar 31, 2025 | -53,000.00 |
| Dec 31, 2024 | -1.30 Mn |
| Dec 31, 2024 | -1.30 Mn |
| Sep 30, 2024 | -113,000.00 |
| Sep 30, 2024 | -113,000.00 |
| Jun 30, 2024 | -142,000.00 |
| Jun 30, 2024 | -142,000.00 |
| Mar 31, 2024 | -170,000.00 |
| Mar 31, 2024 | -170,000.00 |
| Dec 31, 2023 | -1.67 Mn |
| Dec 31, 2023 | -1.67 Mn |
| Sep 30, 2023 | -224,000.00 |
| Sep 30, 2023 | -224,000.00 |
| Jun 30, 2023 | -250,000.00 |
| Jun 30, 2023 | -250,000.00 |
| Mar 31, 2023 | -275,000.00 |
| Mar 31, 2023 | -275,000.00 |
| Dec 31, 2022 | -2.26 Mn |
| Dec 31, 2022 | -2.26 Mn |
| Sep 30, 2022 | -324,000.00 |
| Sep 30, 2022 | -324,000.00 |
| Jun 30, 2022 | -363,000.00 |
| Jun 30, 2022 | -363,000.00 |
| Mar 31, 2022 | -64,000.00 |
| Mar 31, 2022 | -64,000.00 |
| Dec 31, 2021 | -1.85 Mn |
| Dec 31, 2021 | -1.85 Mn |
| Sep 30, 2021 | -153,000.00 |
| Sep 30, 2021 | -153,000.00 |
| Jun 30, 2021 | -195,000.00 |
| Jun 30, 2021 | -195,000.00 |
| Dec 31, 2020 | -797,044.00 |
| Dec 31, 2020 | -797,044.00 |
| Dec 31, 2019 | 991,453.00 |
| Dec 31, 2019 | 991,453.00 |
| Dec 31, 2018 | 992,571.00 |
| Dec 31, 2018 | 992,571.00 |
| Dec 31, 2017 | 994,811.00 |
| Dec 31, 2017 | 994,811.00 |
| Dec 31, 2016 | 994,328.00 |
| Dec 31, 2016 | 994,328.00 |
| Dec 31, 2015 | 971,751.00 |
| Dec 31, 2015 | 971,751.00 |
| Dec 31, 2014 | 784,497.00 |
| Dec 31, 2014 | 784,497.00 |
| Dec 31, 2013 | 577,105.00 |
| Dec 31, 2013 | 577,105.00 |
| Dec 31, 2012 | 654,041.00 |
| Dec 31, 2012 | 654,041.00 |
| Dec 31, 2011 | 614,821.00 |
| Dec 31, 2011 | 614,821.00 |